Trial · NCT05187793
Study of Efficacy of Different Treatment Regimens of Olokizumab
NCT05187793, Phase 3, Unknown, R-Pharm
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Efficacy of Different Treatment Regimens of Olokizumab. Trials, record NCT05187793. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05187793
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Efficacy of Different Treatment Regimens of Olokizumab
- NCT number
- NCT05187793
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 198 participants, actual
- Lead sponsor
- R-Pharm
- Conditions
- COVID-19
- Interventions
- Olokizumab, Standard therapy
- First posted
- 2022-01-12
- Last updated
- 2023-02-13
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical recovery rate at day 7 | Up to day 7 | Clinical recovery defined as score of 3 or less on a 10-point ordinal scale of clinical improvement. (From 0 "Healthy - no clinical manifestations, no viral RNA detected" to 10 "Death".) 7 days are counted from the day of the first administration / intake of study therapy / comparison therapy, depending on study group. Criteria for transition from category "4" to category "3" (criteria for potential discharge): body temperature \< 37 °C; respiratory rate ≤ 20 per minute; SpO2 ≥ 95% without oxygen support, CRP \< 10 mg/l. If any emergency procedures should be prescribed and/or signs of progression on CT are detected, the patient cannot be discharged/transferred to category "3". (In the case of the "rescue" therapy use or the development of clinical deterioration (an increase in the score by 1 point or more) during the follow-up period in a previously recovered patient, the patient is not considered as a "responder", i.e., who has reached the primary endpoint.) |
| Secondary | Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 28, depending on study group | Up to day 28 | Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 28, depending on study group |
| Secondary | CRP normalization rate | Up to Day 28 | Normalization is defined as CRP blood level within normal range (\< 10 mg/l), assessed on days 5, 10, 14, 28, depending on study group. |
| Secondary | Ferritin normalization rate | Up to Day 28 | Normalization is defined as ferritin blood level within normal range, assessed on days 5, 10, 14, 28, depending on study group. |
| Secondary | D-dimer normalization rate | Up to Day 28 | Normalization is defined as D-dimer blood level within normal range, assessed on days 5, 10, 14, 28, depending on study group. |
| Secondary | Mean CRP levels | Up to Day 28 | Mean CRP levels assessed on days 5, 10, 14, 28, depending on study group |
| Secondary | Mean ferritin levels | Up to Day 28 | Mean ferritin levels assessed on days 5, 10, 14, 28, depending on study group |
| Secondary | Mean D-dimer levels | Up to Day 28 | Mean D-dimer levels assessed on days 5, 10, 14, 28, depending on study group |
| Secondary | Rate of prescribing other anti-inflammatory therapy regimens (rescue therapy), depending on study group | Up to day 28 | Rate of prescribing other anti-inflammatory therapy regimens (rescue therapy), depending on study group |
| Other | Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 7, depending on study group | Up to day 7 | Rate of clinical deterioration by at least 1 point from the baseline ordinal score at day 7, depending on study group |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05187793
GET https://conductscience.org/api/trials/v1/NCT05187793/registered?page=2